2023 - A Coruña - Spain

2023 - A Coruña - Spain

Thirty-first meeting, 27-30 June, 2023




18:30-21:30 Registration at the Conference Venue
18:30-21:30 Opening Ceremony, Welcome Reception





8:00-8:45 Registration at the Conference
8:45-9:00 Welcome and Introduction

Oscar Della Pasqua and Thomas Dorlo

9:00-10:00 New Modeling Approaches

Marylore Chenel & Rob ter Heine

9:00-9:20 Nikolaos Alimpertis The estimates for the absorption rate constant in pharmacokinetics and pharmacometrics are wrong: A new era based on the finite absorption time concept rises
9:20-9:40 Robin Chaux Meta-analysis of parameter estimates of non-linear mixed effect models using Approximate Bayesian Computation: application to population pharmacokinetics
9:40-10:00 Mohamed Gewily A Semi Parametric Method for the Estimation of End of Treatment Effect
10:00-11:30 Coffee Break, Software, and Poster Session I
11:30-12:30 Pediatric Extrapolation

Kristin Karlsson, Nick Holford, & Rocio Lledo

11:30-11:50 Kristin Karlsson Paediatric Extrapolation - Opportunities and Challenges
11:50-12:10 Italo Poggesi Extrapolating treatment to children less than 6 years old: the successful story of velmanase alfa in alpha-mannosidosis
12:10-12:30 Bart van Lieshout Population pharmacokinetic analysis of guanabenz in children with Vanishing White Matter: Evaluating scaling adult drug safety and pharmacokinetics data
12:30-14:00 Lunch
14:00-14:50 A tutorial on machine learning & pharmacometrics

Gilbert Koch & Martin Bergstrand

14:00-14:50 Nadia Terranova and Uri Nahum Artificial Intelligence and Machine Learning for Next-Generation Model-Informed Precision Medicine: A Tutorial on Practical Applications and Pitfalls
14:50-15:30 Machine Learning in Pharmacometrics

Gilbert Koch & Martin Bergstrand

14:50-15:10 Antari Khot Do tree-based machine learning methods outperform Cox regression for progression-free survival prediction in mobocertinib treated lung cancer patients?
15:10-15:30 Ana Victoria Ponce Bobadilla Benefits of integrating machine learning with clinical pharmacology principles for predictive pharmacokinetic modeling
15:30-15:35 RedIF Announcement

Darlene Santiago

15:35-17:00 Coffee Break, Software, and Poster Session II
17:05-17:45 Neurodegenerative diseases

Monica Simeoni

17:05-17:25 Alzahra Hamdan Item Response Theory Analysis of the Scale for the Assessment and Rating of Ataxia in Autosomal Recessive Cerebellar Ataxias
17:25-17:45 Alessio Paris An age-dependent QSP model of Nf trafficking to optimize treatment in neurodegenerative diseases





8:30-10:10 Lewis Sheiner Student Session

Paolo Denti, Maria Kjellsson, and Stefanie Hennig

8:30-8:55 Conor O'Hanlon A framework for drug pharmacokinetics during cardiopulmonary bypass
8:55-9:20 Alexander Janssen A generative and causal pharmacokinetic model for haemophilia A: towards an unified model for all factor VIII concentrates.
9:20-9:45 Alessandro De Carlo Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat
9:45-10:10 Alexandra Lavalley-Morelle Joint modeling of biomarkers dynamics and survival with competing risks to predict the prognostic of patients hospitalized with severe infectious diseases
10:10-10:15 Presentation Lewis Sheiner Student Session Awards
10:15-11:45 Coffee Break, Software, and Poster Session III
11:45-12:25 Modelling Antibody Responses

Thomas Dorlo

11:45-12:05 Iñaki F. Trocóniz Modeling the dynamics of anti-drug antibodies in cancer patients treated with oncolytic virus in monotherapy or in combination with immune check- point inhibitors
12:05-12:25 Quentin Clairon Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2 vaccine
12:25-13:55 Lunch
13:55-14:40 Keynote Lecture

Dinesh de Alwis & Lena Friberg

13:55-14:40 Alexandra Snyder Current and future applications of circulating tumor DNA (ctDNA) to oncology drug development
14:40-15:20 Tumor Growth Dynamics

Dinesh de Alwis & Lena Friberg

14:40-15:00 Yomna Nassar A joint tumour dynamics and C-reactive protein turnover model to identify early longitudinal prognostic predictors of overall survival in advanced non-small cell lung cancer patients
15:00-15:20 Anna Kondic The combined use of propensity score matching and a joint tumor growth dynamics (TGD) - Overall Survival (OS) model to benchmark the efficacy of new treatments for advanced renal cell carcinoma (RCC)
15:20-15:25 ACoP Announcement

Wei Gao

15:25-16:55 Coffee Break, Software, and Poster Session IV
16:55-17:55 Stuart Beal Methodology Session

Ana Ruiz

16:55-17:15 Freya Bachmann Computing Optimal Drug Dosing with Constraints on Model States in NONMEM
17:15-17:35 Dominic Bräm Neural ODE structures based on pharmacokinetic principles
17:35-17:55 Zhonghui Huang Development and exploration of exhaustive, stepwise, and heuristic algorithms for automated population pharmacokinetic modelling
20:30-2:00 Social Event





9:15-10:15 QSP & PBPK Disease Models

Oscar Della Pasqua

9:15-9:35 Joey Leung Virtual population analysis of a Quantitative Systems Pharmacology (QSP) model of atopic dermatitis (AtD) to evaluate AtD treatments
9:35-9:55 Natalia Riva Expanding a quantitative systems pharmacology (QSP) modeling framework for acute Hepatitis B to characterize chronic infection
9:55-10:15 Robin Michelet Development and Application of a Minimal Physiology-based Pharmacokinetics Modelling Framework to Predict Tumor Penetration and Receptor Occupancy.
10:15-10:20 Preview of PAGE 2024
10:20-10:55 Coffee Break
10:55-11:55 Model Diagnostics

Siv Jönsson

10:55-11:15 Martin Bergstrand Application relevant shrinkage metrics
11:15-11:35 Sarah Baklouti Multivariate Exact Discrepancy : a new tool for PK/PD model evaluation
11:35-11:55 Stefanie Hennig Considerations when deriving time-averaged exposure for censored subjects for logistic regression exposure-response analyses
11:55-12:05 Closing remarks
12:05-12:20 Audience Input for potential PAGE 2024 topics